BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET

PR Newswire

SAN RAFAEL, Calif., Oct. 26, 2026

SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m. ET to discuss third quarter 2026 financial results and provide a general business update.

BioMarin Pharmaceutical logo

Dial-in Number 
U.S. / Canada Dial-in Number: +1 833-461-5787
International Dial-in Number: +1 626-884-3620
Conference Call ID: 324 588 583

U.S. / Canada Replay Dial-in Number: +1 833-309-1852
International Replay Dial-in Number: +44 800 007 4044
Playback ID: 324 588 583 

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com. 

Contacts:




Investors

Media

Traci McCarty

Marni Kottle

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(650) 374-2803

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-third-quarter-2026-financial-results-conference-call-and-webcast-on-monday-november-2-2026-at-430pm-et-302918505.html

SOURCE BioMarin Pharmaceutical Inc.